EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Survey of practices in the European Federation for Colposcopy: HPV vaccination after treatment for cervical precancerous lesions

Annu Heinonen iD, Ilkka Kalliala, Anne Hammer iD, Maggie Cruickshank, Xavier Carcopino, Björn Strander, Pekka Nieminen

Acta Obstetricia et Gynecologica Scandinavica · 2025

DOI: 10.1111/aogs.70027 ↗

At a glance

Journal article in Acta Obstetricia et Gynecologica Scandinavica, 2025. Written by Annu Heinonen and 6 co-authors. Institution: Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Major MEDLINE topics: Papillomavirus Vaccines, Uterine Cervical Neoplasms, Papillomavirus Infections, Precancerous Conditions. Cited 1 times so far (Crossref); 21 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Introduction

Patients treated for cervical precancerous lesions have a long‐term increased risk for cervical cancer compared with the general population. As human papillomavirus (HPV) vaccination is effective in preventing cervical cancer and its precursors when given prior to sexual debut, adjuvant HPV vaccination in relation to the treatment of precursor lesions has been of great interest. Existing supporting data are of low quality, and recent meta‐analyses called for high‐quality randomized controlled trials. The European Federation for Colposcopy (EFC) observed a heterogeneity in clinical practices of adjuvant vaccination, and this survey aimed to assess potential differences in vaccination practices across Europe. Material and Methods A survey was sent out to 100 representatives of the 32 member countries of the EFC. The survey was in English and contained questions on current general HPV vaccination programs, whether guidelines on vaccination after treatment exist, and questions on respondents' own practices of recommending vaccination after treatment. The survey was constructed using the Google Forms web platform and sent by email to representatives of each National Colposcopy Society.

Results

In total, 44 answers from 32 different European countries were received. Overall, 12 countries (12/32, 37.5%) reported having a national guideline on HPV vaccination at the time of treatment for precursor lesions, and in nine of these countries, adjuvant HPV vaccination is recommended. A third, 31.8%, of respondents (14/44) found the available evidence sufficient to recommend vaccination at the time of treatment, and 54.5% (24/44) found the evidence to be nearly sufficient. Only 13.6% (6/44) of the respondents found the current evidence insufficient to be able to recommend vaccination. Altogether, 29.5% (13/44) of respondents would recommend vaccination, even if future randomized controlled trials would not show benefits.

Conclusions

The varying practices regarding adjuvant HPV vaccination across European countries are concerning and call for ethical evidence‐based practices across Europe and reliance on high‐quality evidence to assess whether vaccination at the time of treatment is effective.

Subjects

MeSH terms (MEDLINE)

Papillomavirus VaccinesUterine Cervical NeoplasmsPapillomavirus InfectionsPrecancerous ConditionsPractice Patterns, Physicians'VaccinationUterine Cervical DysplasiaHumansFemaleEuropeColposcopySurveys and QuestionnairesHealth Care Surveys

Author keywords

HGIL treatmentHPV‐vaccinationadjuvant HPV vaccination

Substances

Papillomavirus Vaccines

Authors and institutions

  • Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Department of Metabolism, Digestion and Reproduction and Department of Surgery and Cancer, Faculty of Medicine, Institute of Reproductive and Developmental Biology, Imperial College, London, UK.
  • University Clinic for HPV-Related Gynecological Disease, Department of Obstetrics and Gynecology, Gødstrup Hospital, Herning, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Aberdeen Centre for Women's Health Research, Aberdeen Maternity Hospital, University of Aberdeen, Aberdeen, UK.
  • Department of Obstetrics and Gynecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), Univ Avignon, CNRS, IRD, IMBE UMR 7263, Marseille, France.

ORCID profiles: Annu Heinonen, Anne Hammer

Cite

APA

Heinonen, A., Kalliala, I., Hammer, A., Cruickshank, M., Carcopino, X., Strander, B., & Nieminen, P. (2025). Survey of practices in the European Federation for Colposcopy: HPV vaccination after treatment for cervical precancerous lesions. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70027

Vancouver

Heinonen A, Kalliala I, Hammer A, Cruickshank M, Carcopino X, Strander B, et al. Survey of practices in the European Federation for Colposcopy: HPV vaccination after treatment for cervical precancerous lesions. Acta Obstetricia et Gynecologica Scandinavica. 2025. doi:10.1111/aogs.70027

BibTeX
@article{Heinonen2025,
  author = {Heinonen, Annu and Kalliala, Ilkka and Hammer, Anne and Cruickshank, Maggie and Carcopino, Xavier and Strander, Björn and Nieminen, Pekka},
  title = {Survey of practices in the European Federation for Colposcopy: HPV vaccination after treatment for cervical precancerous lesions},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2025},
  doi = {10.1111/aogs.70027}
}
Start for free →